COVID-19 vaccination timing and kidney transplant waitlist management: An international perspective [0.03%]
COVID-19疫苗接种时机与肾脏移植等候名单管理：一个国际视角
Yasar Caliskan,David Axelrod,Alexis Guenette et al.
Yasar Caliskan et al.
Background: The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for solid organ transplant programs worldwide. The aim of this study is to assess an international perspective on challenge...
Majocchi's granuloma in a patient with GATA2 haploinsufficiency undergoing hematopoietic stem cell transplantation [0.03%]
造血干细胞移植的GATA2单倍不足患者中的Majocchi肉芽肿
Claudie Roy,Sara Belga,Valery Lavergne et al.
Claudie Roy et al.
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients [0.03%]
实体器官移植受者单克隆抗体治疗COVID-19
Bonnie Ann Sarrell,Karen Bloch,Alissar El Chediak et al.
Bonnie Ann Sarrell et al.
Solid organ transplant (SOT) recipients are at high risk for severe coronavirus disease 2019 (COVID-19). Studies suggest that early intervention with monoclonal antibody (MAB) treatment directed against the SARS-CoV-2 spike protein may redu...
Prevalence and outcomes of Clostridioides difficile infection in liver transplant recipients [0.03%]
肝移植受者中的艰难梭菌感染的患病率与预后
Nicholas C Kortt,Cositha Santhakumar,Rebecca J Davis et al.
Nicholas C Kortt et al.
Background and aim: Data are limited on whether Clostridioides difficile infection (CDI) in the first year after liver transplantation (LT) is associated with increased mortality. In an Australian setting without hypervir...
Short-term liver transplant outcomes from SARS-CoV-2 lower respiratory tract NAT positive donors [0.03%]
来自SARS-CoV-2下呼吸道NAT检测阳性供体的短期肝脏移植结果
Ricardo M La Hoz,Arjmand R Mufti,Parsia A Vagefi
Ricardo M La Hoz
On April 2021, the United States Organ Procurement and Transplantation Executive Committee approved the "lower respiratory SARS-CoV-2 testing for lung donors" emergency policy upon recommendation from the Ad Hoc Disease Transmission Advisor...
A multicenter evaluation of hepatitis B reactivation with and without antiviral prophylaxis after kidney transplantation [0.03%]
肾移植后有无抗病毒预防的乙型肝炎再激活的多中心评价
Suhail A Shaikh,Jeffrey Kahn,Andraea Aksentijevic et al.
Suhail A Shaikh et al.
Background: Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody (anti-HBc)-positive kidney transplant recipients ranges between 1.4% and 9.6%. Limited evidenc...
Recurrent nocardiosis in solid organ transplant recipients: An evaluation of secondary prophylaxis [0.03%]
实体器官移植受者中复发的诺卡菌病：二次预防效果评估
Zachary A Yetmar,John W Wilson,Elena Beam
Zachary A Yetmar
Background: Immunocompromised individuals are at risk for Nocardia infection, with a recurrence rate of approximately 5%. Solid organ transplant (SOT) recipients often receive secondary prophylaxis due to their requiremen...
Epstein-Barr virus associated smooth muscle neoplasm postlung transplantation [0.03%]
肺移植后与埃博拉病毒相关的平滑肌肿瘤
Samantha Ennis,Marshall Plit,Monique Malouf
Samantha Ennis
Small bowel transplantation from SARS-CoV-2 respiratory PCR positive donors: Is it safe? [0.03%]
来自SARS-CoV-2呼吸道PCR阳性供体的小肠移植：安全吗？
Yoichiro Natori,Shweta Anjan,Jacques Simkins et al.
Yoichiro Natori et al.
Use of anti-CMV immunoglobulins in lung transplant recipients: The French experience [0.03%]
肺移植受者使用抗CMV免疫球蛋白：法国经验
Roy Charlotte,Parquin François,Messika Jonathan et al.
Roy Charlotte et al.
Rational: Pending the authorization of new anti-CMV drugs with fewer adverse effects, exploring the possibilities offered by CMV immunoglobulins (CMVIG) seems necessary. In France, access to CMVIG requires official author...